Results 151 to 160 of about 4,106 (260)
"Good and bad investments" in public health stocks amid the COVID-19 shock: evidence from a transformer-based model. [PDF]
Zhao D, Li Y, Gu R.
europepmc +1 more source
Essays on Testing Long-Run Abnormal Stock Returns
fi=vertaisarvioitu|en=peerReviewed|
openaire +1 more source
Quantifying the Linguistic Complexity of Pan-Homophonic Events in Stock Market Volatility Dynamics. [PDF]
Zhang Y, Tian J, Zou Y, Zhang X, Cai X.
europepmc +1 more source
Effects of Corporate Greenwashing on Firm Value in China
ABSTRACT In response to rising public expectations for corporate environmental sustainability, instances of greenwashing have emerged as firms seek to alleviate regulatory pressure and mitigate reputational risks. This study examines the nonlinear economic consequences of corporate greenwashing by analyzing panel data from A‐share listed firms in China
Run Kong, Byungkwon Lim, Hyang Mi Choi
wiley +1 more source
Advanced investing with deep learning for risk-aligned portfolio optimization. [PDF]
Nguyen MD.
europepmc +1 more source
ABSTRACT This paper examines whether institutional ownership with different investment horizons is related to corporate breakthrough innovation, using panel data of Chinese A‐share listed firms from 2014 to 2023. Long‐term institutional ownership is positively and significantly associated with breakthrough innovation, while short‐term institutional ...
He Zeng +3 more
wiley +1 more source
Abstract Background The posterior subthalamic area (PSA) is a familiarized target for Parkinson's disease (PD) in the lesioning era and has recently been reconsidered for deep brain stimulation (DBS). Objective The aim of this study was to compare the therapeutic efficacy of PSA versus subthalamic nucleus (STN) DBS in tremor‐dominant Parkinson's ...
Zhengyu Lin +7 more
wiley +1 more source
Financial frictions and stock return: A novel least minus more frictional factor for asset pricing models in emerging economies. [PDF]
Khan S +4 more
europepmc +1 more source
ABSTRACT Objective The safety, tolerability, pharmacokinetics, and efficacy of TERN‐601, a once‐daily, oral small‐molecule glucagon‐like peptide‐1 (GLP‐1) receptor agonist, were studied in Phase 1 and 2 clinical studies. Methods The Phase 1 (28‐day) and Phase 2 (12‐week), randomized, double‐blind, placebo‐controlled, multiple‐ascending‐dose studies ...
W. Timothy Garvey +11 more
wiley +1 more source

